-SEC Filing
SVB Leerink Maintains Outperform on Affimed, Lowers Price Target to $6
SVB Leerink analyst Daina Graybosch maintains Affimed (NASDAQ:AFMD) with a Outperform and lowers the price target from $10 to $6.
Related Posts
Verve Therapeutics Q3 EPS $(0.47) Up From $(3.81) YoY
Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.47) per share. This is a 87.66 percent increase over losses of $(3.81) per share from the same period last year.
Recap: Kandi Technologies Q2 Earnings
Shares of Kandi Technologies Gr (NASDAQ:KNDI) moved higher by 1.2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 33.33% year over year to ($0.08), which beat the estimate of ($0.18).
Mawson Infrastructure Group Highlights Release Of Report ‘Cryptocurrency and The Distributed Digital Economy in Australia’
Key report findings
In 2021, the cryptocurrency and digital asset sector will contribute $2.1bn to the Australian economy and employ around 11,600 people.
With reform and growth, this could increase to a contribution